Search research articles
Contact Us
Filters
Showing results (11-20 of 31) with videos related to
Page
of 4
Sort By:
Clinicoeconomics and Outcomes Research : CEOR
|
October 23, 2023
Cost-Effectiveness of Acthar Gel versus Standard of Care for the Treatment of Advanced Symptomatic Sarcoidosis
Jas Bindra, Ishveen Chopra, Kyle Hayes, et al.
BMC Musculoskeletal Disorders
|
September 2, 2020
Repository corticotropin injection attenuates collagen-induced arthritic joint structural damage and has enhanced effects in combination with etanercept
Dima A Decker, Paul Higgins, Kyle Hayes, et al.
Advances in Therapy
|
October 20, 2022
Cost-Effectiveness of Acthar Gel Versus Standard of Care for the Treatment of Exacerbations in Moderate-to-Severe Systemic Lupus Erythematosus
Jas Bindra, Ishveen Chopra, Kyle Hayes, et al.
Journal of Comparative Effectiveness Research
|
January 28, 2026
Acthar Gel versus standard of care for adults with proteinuria in nephrotic syndrome due to focal segmental glomerulosclerosis: cost-per-response analysis from the US healthcare perspective
Jas Bindra, Ishveen Chopra, Kyle Hayes, et al.
Clinicoeconomics and Outcomes Research : CEOR
|
March 16, 2026
Adherence to Acthar Gel (RCI) and Outcomes in Patients with Membranous Nephropathy: A Claims Database Analysis
Kyle Hayes, Mohammed Fahim, Feng Sheng Hu, et al.
Journal of Comparative Effectiveness Research
|
July 17, 2025
Cost-per-response of Acthar Gel versus standard of care for the treatment of noninfectious keratitis: a United States healthcare perspective
Jas Bindra, Ishveen Chopra, Kyle Hayes, et al.
Journal of Health Economics and Outcomes Research
|
May 9, 2022
Understanding Predictors of Response to Repository Corticotropin Injection Treatment Among Patients With Advanced Symptomatic Sarcoidosis
Jas Bindra, Ishveen Chopra, Kyle Hayes, et al.
Journal of Health Economics and Outcomes Research
|
August 11, 2025
Cost per Response of Acthar® Gel vs Standard of Care for the Treatment of Proteinuria in Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy Among Adults from the US Healthcare Perspective
Jas Bindra, Ishveen Chopra, Kyle Hayes, et al.
Therapeutics and Clinical Risk Management
|
February 14, 2024
Acthar Gel in African Americans versus Non-African Americans with Symptomatic Sarcoidosis: Physician Assessment of Patient Medical Records
Jas Bindra, Ishveen Chopra, Kyle Hayes, et al.
Open Access Rheumatology : Research and Reviews
|
September 17, 2025
Treatment Patterns and Outcomes of Acthar Gel in Ankylosing Spondylitis and Psoriatic Arthritis: A Physician-Reported Chart Review
Amit Patel, Priyanka P Shanbhag, Destri R Evans, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 31) with videos related to
Sort By:
Page
of 4
Clinicoeconomics and Outcomes Research : CEOR
|
October 23, 2023
Cost-Effectiveness of Acthar Gel versus Standard of Care for the Treatment of Advanced Symptomatic Sarcoidosis
Jas Bindra, Ishveen Chopra, Kyle Hayes, et al.
BMC Musculoskeletal Disorders
|
September 2, 2020
Repository corticotropin injection attenuates collagen-induced arthritic joint structural damage and has enhanced effects in combination with etanercept
Dima A Decker, Paul Higgins, Kyle Hayes, et al.
Advances in Therapy
|
October 20, 2022
Cost-Effectiveness of Acthar Gel Versus Standard of Care for the Treatment of Exacerbations in Moderate-to-Severe Systemic Lupus Erythematosus
Jas Bindra, Ishveen Chopra, Kyle Hayes, et al.
Journal of Comparative Effectiveness Research
|
January 28, 2026
Acthar Gel versus standard of care for adults with proteinuria in nephrotic syndrome due to focal segmental glomerulosclerosis: cost-per-response analysis from the US healthcare perspective
Jas Bindra, Ishveen Chopra, Kyle Hayes, et al.
Clinicoeconomics and Outcomes Research : CEOR
|
March 16, 2026
Adherence to Acthar Gel (RCI) and Outcomes in Patients with Membranous Nephropathy: A Claims Database Analysis
Kyle Hayes, Mohammed Fahim, Feng Sheng Hu, et al.
Journal of Comparative Effectiveness Research
|
July 17, 2025
Cost-per-response of Acthar Gel versus standard of care for the treatment of noninfectious keratitis: a United States healthcare perspective
Jas Bindra, Ishveen Chopra, Kyle Hayes, et al.
Journal of Health Economics and Outcomes Research
|
May 9, 2022
Understanding Predictors of Response to Repository Corticotropin Injection Treatment Among Patients With Advanced Symptomatic Sarcoidosis
Jas Bindra, Ishveen Chopra, Kyle Hayes, et al.
Journal of Health Economics and Outcomes Research
|
August 11, 2025
Cost per Response of Acthar® Gel vs Standard of Care for the Treatment of Proteinuria in Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy Among Adults from the US Healthcare Perspective
Jas Bindra, Ishveen Chopra, Kyle Hayes, et al.
Therapeutics and Clinical Risk Management
|
February 14, 2024
Acthar Gel in African Americans versus Non-African Americans with Symptomatic Sarcoidosis: Physician Assessment of Patient Medical Records
Jas Bindra, Ishveen Chopra, Kyle Hayes, et al.
Open Access Rheumatology : Research and Reviews
|
September 17, 2025
Treatment Patterns and Outcomes of Acthar Gel in Ankylosing Spondylitis and Psoriatic Arthritis: A Physician-Reported Chart Review
Amit Patel, Priyanka P Shanbhag, Destri R Evans, et al.
Page
of 4